A Study on Relationship Between Resected Normal Liver Parenchymal Volume(RNLV)and Post-Hepatectomy Liver Failure (PHLF)
RNLV
A Model Based on Resected Normal Liver Parenchymal Volume(RNLV)to Predict the Risk of Post-Hepatectomy Liver Failure (PHLF)
1 other identifier
observational
1,600
1 country
3
Brief Summary
The post-hepatotectomy liver failure (PHLF) is still the most worrisome complication of hepatic resection. Surgeons have always been making efforts to preoperatively predict PHLF using kinds of techniques, scoring systems, and variables. The investigators of this study tried to create an individual predictive model based on the variable, resected normal parenchymal volume (RNLV), then assessing the performance and value of the model in clinical practice.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Dec 2022
Longer than P75 for all trials
3 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 1, 2022
CompletedFirst Submitted
Initial submission to the registry
April 10, 2024
CompletedFirst Posted
Study publicly available on registry
April 15, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 31, 2026
April 14, 2026
April 1, 2026
4.1 years
April 10, 2024
April 9, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Probability of PHLF was predicted with our individual model based on RNLV.
In our center, an increase international normalized ratio greater than 1.15 and concomitant hyperbilirubinemia more than 23μmol/L on or after postoperative day 5 would be defined as PHLF, according to the International Study Group of Liver Surgery.
postoperative day 1 to day 30.
Study Arms (2)
PHLF group
One group was defined as post-operative liver failure accroding to the PHLF definition of 50-50 criteria and ISGLS criteria.
No PHLF group
One group was defined as no post-operative liver failure accroding to the PHLF definition of 50-50 criteria nor ISGLS criteria.
Interventions
Our study respectively defined the PHLF according to the 50-50 criteria and the ISGLS criteria in literature review.
Eligibility Criteria
1133 consecutive patients diagnosed with hepatocellular carcinoma (HCC) and intracholangiocarcinoma underwent hepatectomies.
You may qualify if:
- selective hepatectomies;
- histologically confirmed as HCC and ICC
- complete and accessible data
You may not qualify if:
- any history of Associated Liver Partition and Portal vein ligation for Staged hepatectomy (ALPPS)
- any history of portal vein embolism (PVE)
- any history of tumor rupture
- emergency surgery
- pathologically diagnosed with neither HCC nor ICC
- concomitant resection of gastrointestinal organs, spleenectomy or other organs
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (3)
Mengchao Hepatobiliary Hospital of Fujian Medical University
Fujian, Shanghai Municipality, China
The Third Affiliated Hospital of Naval Medical University
Shanhai, Shanghai Municipality, 201800, China
Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen, Mengchao Hepatobiliary Hospital of Fujian Medical University
Shenzhencun, Shanghai Municipality, China
Related Publications (4)
Ioannou GN, Green P, Kerr KF, Berry K. Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification. J Hepatol. 2019 Sep;71(3):523-533. doi: 10.1016/j.jhep.2019.05.008. Epub 2019 May 28.
PMID: 31145929BACKGROUNDXie DY, Ren ZG, Zhou J, Fan J, Gao Q. 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights. Hepatobiliary Surg Nutr. 2020 Aug;9(4):452-463. doi: 10.21037/hbsn-20-480.
PMID: 32832496BACKGROUNDRenner P, Schuhbaum J, Kroemer A, Zeman F, Loss M, Lang SA, Geissler EK, Schlitt HJ, Farkas SA. Morbidity of hepatic resection for intermediate and advanced hepatocellular carcinoma. Langenbecks Arch Surg. 2016 Feb;401(1):43-53. doi: 10.1007/s00423-015-1359-y. Epub 2015 Dec 1.
PMID: 26627084BACKGROUNDXie QS, Chen ZX, Zhao YJ, Gu H, Geng XP, Liu FB. Systematic review of outcomes and meta-analysis of risk factors for prognosis after liver resection for hepatocellular carcinoma without cirrhosis. Asian J Surg. 2021 Jan;44(1):36-45. doi: 10.1016/j.asjsur.2020.08.019. Epub 2020 Sep 28.
PMID: 32988708BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Yuan-yuan Wang
Eastern Hepatobiliary Surgery Hospital
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER GOV
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- a clinical resident of general surgery department
Study Record Dates
First Submitted
April 10, 2024
First Posted
April 15, 2024
Study Start
December 1, 2022
Primary Completion (Estimated)
December 31, 2026
Study Completion (Estimated)
December 31, 2026
Last Updated
April 14, 2026
Record last verified: 2026-04
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, ICF, CSR, ANALYTIC CODE
- Time Frame
- After our paper published officially. The final time would be end of March 31st,2024.
- Access Criteria
- Not sure now.
After we published our study paper, we would like to share IPD attached to our paper as website links.